Related Experiment Video

Updated: Oct 1, 2026

Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model
06:07

Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model

Published on: June 23, 2023

Parkinson syndrome as a manifestation of mitochondriopathy

J Finsterer1

  • 1Ludwig Boltzmann Institute for Epilepsy and Neuromuscular Disorders, Postfach 348, 1180 Vienna, Austria. duarte@jet2web.cc

Acta Neurologica Scandinavica
|May 2, 2002
PubMed
Abstract

Insights

Parkinson syndrome (PS) affects 12% of mitochondriopathy (MCP) patients, while 6% of PS patients show MCP features. Both conditions benefit from Parkinson

Area of Science:

  • Neurology
  • Mitochondrial Diseases
  • Movement Disorders

Background:

  • Growing evidence links Parkinson syndrome (PS) and mitochondriopathy (MCP).
  • The prevalence of PS in MCP patients remains largely unknown.
  • Understanding this relationship is crucial for comprehensive patient care.

Purpose of the Study:

  • To determine the frequency of PS in patients diagnosed with MCP.
  • To characterize the clinical phenotype of MCP patients with PS.
  • To evaluate the efficacy of anti-Parkinsonian medications in this cohort.

Main Methods:

  • Prospective study over a 1-year period.
  • Assessed PS diagnosis in 76 MCP patients.
  • Evaluated MCP prevalence in 144 PS patients.

Main Results:

  • PS was diagnosed in 12% of MCP patients (9 out of 76).
  • MCP was identified in 6.3% of PS patients (144 total).
  • MCP patients with PS exhibited multisystem involvement and responded well to standard anti-Parkinsonian drugs.

Conclusions:

  • A significant percentage of MCP patients exhibit PS features, and vice versa.
  • Multisystemic involvement is common in MCP patients with PS.
  • Anti-Parkinsonian therapies are effective for PS in the context of MCP.

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...